



Strategic Programs

Improving the Efficiency of the Medical Research Enterprise

Consider that there are more than 10,000 known deadly and debilitating diseases affecting our world today. Of those, only about 500 of them can be treated effectively. Fewer than half of these known diseases have organizations dedicated to accelerating cures. The complexity of human biology, bureaucracy, inefficiency, and lack of funding are stalling progress.

That's where *FasterCures* comes in. Looking across diseases, we bring together patient advocates, researchers, investors, and policymakers from every sector of the medical research and development (R&D) system to identify and eliminate the road-blocks that get in the way of progress.

FASTERCURES PROGRAMS 2014

Our programs are driven by a singular goal—to save lives by speeding up and improving the medical research system.

The Research Acceleration and Innovation Network (TRAIN)

TRAIN helps scale effective solutions by connecting resources, tools, and relationships created by disruptive innovators in health and medicine. The 60 foundations that form the TRAIN network

range from large organizations like the American Heart Association and Alzheimer's Association to startup foundations focused on rare disorders like chordoma. We create opportunities to share what they've learned about fixing the research system so that all diseases have a better chance for finding effective therapies.

Philanthropy Advisory Service

For diseases that lack a focused research effort, the Philanthropy Advisory Service (PAS) can provide a landscape analysis of the most promising research, connect potential philanthropic funders, and advise on investment opportunities that will advance better health outcomes.

Partnering for Cures

Each year at our Partnering for Cures conference, more than 1,000 leaders come together and figure out how to pool human and financial capital to address common challenges. It has become the go-to meeting for those seeking innovative, cross-sector partnerships in medical research.

Consortia-pedia

One emerging model for medical research partner- ships is the consortium. In 2013 alone, 46 consortia were formed. Our Consortia-pedia program identifies elements for success, offers tactics to scale models for more efficiency and greater impact, and creates a framework for evaluating returns on investment.

POLICY PROGRAMS

A 21st century bullet train on 19th century steam engine tracks can only go so fast. But that's the system we have for medical research. We focus on addressing antiquated policies that keep us from propelling forward.

Federal Investment in Research

We advocate for robust federal investment in the National Institutes of Health and the the Food and Drug Administration so these these agencies have the resources they need need to turn scientific discoveries into better health.

STAY CONNECTED

SmartBrief

The latest developments in medical research delivered to you every Tuesday and Thursday to keep you current on relevant news.

The *FasterCures* Blog

Insights and perspectives on trends and headlines that impact the productivity of the medical research enterprise.

Social networks

Real-time and relevant updates on social platforms that you trust.

Benefit-Risk Regulatory Framework

The tradeoffs between desired benefits and tolerable risks look quite different whether you're a patient, physician, regulator, or drug or device company. New regulatory policies have created opportunities for industry, patients, and regulators to engage in the benefit and risk discussion. This program expands opportunities for patient perspectives to shape product development and influence regulatory decisions so products patients value advance quicker from bench to bedside.

Value and Coverage

Even if we are successful at getting new treatments through the R&D and approval process, the question remains whether payers—including the federal government—will be willing to pick up the tab. Who determines value and what informs that determination are vastly unclear but have large implications for both the cure and care ecosystems. This effort will explore strategies for patient perspectives to inform coverage decisions and create an environment that incentivizes innovation and ensures access to life-saving therapies.

**FOR MORE INFORMATION ABOUT
FASTERCURES PROGRAMS, VISIT
WWW.FASTERCURES.ORG.**

@fastercures

